The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.e

Organizing pneumonia pattern (an area or areas of consolidation on imaging)

Publications

Molina M, Yellapragada S, Mims M, Rahman E, Rivero G

Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia.

Case reports in hematology 2015;2015;357461 — 2015 — 357461

Alnimer Y, Salah S, Abuqayas B, Alrabi K

Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature.

Journal of medical case reports 2016 Jan 20;10;15 — 2016 Jan 20 — 15

Sekhri A, Palaniswamy C, Kurmayagari K, Kalra A, Selvaraj DR

Interstitial lung disease associated with azacitidine use: a case report.

American journal of therapeutics 2012 Mar;19;e98-e100 — 2012 Mar — e98-e100

Adams CD, Szumita PM, Baroletti SA, Lilly CM

Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome.

Pharmacotherapy 2005 May;25;765-8 — 2005 May — 765-8